IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE 'COMPANY') SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ('SEBI ICDR REGULATIONS') AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED ('COMPANIES ACT').
MAKING THE PRELIMINARY PLACEMENT DOCUMENT DATED MARCH 20, 2024 (THE 'PRELIMINARY PLACEMENT DOCUMENT') AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY EQUITY SHARES OF THE COMPANY ('EQUITY SHARES') IN THE PROPOSED QUALIFIED INSTITUTIONS PLACEMENT ('ISSUE') IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PRELIMINARY PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE 'STOCK EXCHANGES'). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PRELIMINARY PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'U.S. SECURITIES ACT'), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN 'OFFSHORE TRANSACTIONS' AS DEFINED IN AND IN RELIANCE ON REGULATIONS UNDER THE U.S. SECURITIES ACT.
THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PRELIMINARY PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PRELIMINARY PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PRELIMINARY PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PRELIMINARY PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PRELIMINARY PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PRELIMINARY PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PRELIMINARY PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PRELIMINARY PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PRELIMINARY PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PRELIMINARY PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS ('QIBs') WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING THE SEBI ICDR REGULATIONS, ARE ELIGIBLE TO INVEST IN THIS ISSUE ('ELIGIBLE QIBs') IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT. UNLESS A SERIALLY NUMBERED PRELIMINARY PLACEMENT DOCUMENT ACCOMPANIED BY AN APPLICATION FORM IS ADDRESSED TO A SPECIFIC QIB INVITING SUCH QIB TO MAKE A BID THROUGH SUCH APPLICATION FORM, NO OFFER AND/OR INVITATION OF OFFER SHALL BE DEEMED TO HAVE BEEN MADE.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PRELIMINARY PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the “I Confirm” button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked 'I Do Not Confirm'.
IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE 'COMPANY') SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE 'SEBI ICDR REGULATIONS') AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (THE 'COMPANIES ACT').
MAKING THE PLACEMENT DOCUMENT DATED 26 MARCH, 2024 (THE 'PLACEMENT DOCUMENT') AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE EQUITY SHARES OF THE COMPANY ('EQUITY SHARES') IN THE QUALIFIED INSTITUTIONS PLACEMENT (THE 'ISSUE') IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE 'STOCK EXCHANGES'). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'U.S. SECURITIES ACT'), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN 'OFFSHORE TRANSACTIONS' AS DEFINED IN AND IN RELIANCE ON REGULATIONS UNDER THE U.S. SECURITIES ACT.
THE PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS ('QIBs') WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AND MADE AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT YOUR ACCESS TO THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the 'I Confirm' button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked 'I Do Not Confirm'.
IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE “COMPANY”) SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI ICDR REGULATIONS”) AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (THE “COMPANIES ACT”).
MAKING THE PRELIMINARY PLACEMENT DOCUMENT DATED NOVEMBER 6, 2024 (THE “PRELIMINARY PLACEMENT DOCUMENT”) AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE EQUITY SHARES OF THE COMPANY (“EQUITY SHARES”) IN THE PROPOSED QUALIFIED INSTITUTIONS PLACEMENT (THE “ISSUE”) IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PRELIMINARY PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE “STOCK EXCHANGES”). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PRELIMINARY PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN “OFFSHORE TRANSACTIONS” AS DEFINED IN AND IN RELIANCE ON REGULATION S UNDER THE U.S. SECURITIES ACT.
THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PRELIMINARY PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PRELIMINARY PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PRELIMINARY PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PRELIMINARY PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PRELIMINARY PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PRELIMINARY PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PRELIMINARY PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PRELIMINARY PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PRELIMINARY PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PRELIMINARY PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS (“QIBs”) WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT. UNLESS A SERIALLY NUMBERED PRELIMINARY PLACEMENT DOCUMENT ACCOMPANIED BY AN APPLICATION FORM IS ADDRESSED TO A SPECIFIC QIB INVITING SUCH QIB TO MAKE A BID THROUGH SUCH APPLICATION FORM, NO OFFER AND/OR INVITATION OF OFFER SHALL BE DEEMED TO HAVE BEEN MADE.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AND MADE AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT YOUR ACCESS TO THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PRELIMINARY PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the “I Confirm” button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked “I Do Not Confirm”.
IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE “COMPANY”) SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE “SEBI ICDR REGULATIONS”) AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (THE “COMPANIES ACT”).
MAKING THE PLACEMENT DOCUMENT DATED NOVEMBER 6, 2024 (THE “PLACEMENT DOCUMENT”) AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE EQUITY SHARES OF THE COMPANY (“EQUITY SHARES”) IN THE PROPOSED QUALIFIED INSTITUTIONS PLACEMENT (THE “ISSUE”) IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE “STOCK EXCHANGES”). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN “OFFSHORE TRANSACTIONS” AS DEFINED IN AND IN RELIANCE ON REGULATION S UNDER THE U.S. SECURITIES ACT.
THE PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS (“QIBs”) WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT. UNLESS A SERIALLY NUMBERED PLACEMENT DOCUMENT ACCOMPANIED BY AN APPLICATION FORM IS ADDRESSED TO A SPECIFIC QIB INVITING SUCH QIB TO MAKE A BID THROUGH SUCH APPLICATION FORM, NO OFFER AND/OR INVITATION OF OFFER SHALL BE DEEMED TO HAVE BEEN MADE.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AND MADE AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT YOUR ACCESS TO THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the “I Confirm” button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked “I Do Not Confirm”.
Therapeutic Use<\/b><\/td>\n | Brand Name<\/b><\/td>\n | Composition<\/b><\/td>\n <\/tr>\n URINE ALKALIZER<\/td>\n | ALKAWOCK 100ML<\/td>\n | Each 5ml contains: Disodium Hydrogen Citrate BP 1.25g<\/td>\n <\/tr>\n | ANTI-HELMENTICS<\/td>\n | ALZAD 1T<\/td>\n | Each uncoated chewable tablet contains: Albendazole IP 400mg<\/td>\n <\/tr>\n | ANTI-HELMENTICS<\/td>\n | ALZAD SUSP 10ML<\/td>\n | Each 5ml contains: Albendazole IP 200mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | AMLOWOCK- 5<\/td>\n | Each uncoated Tablet Contains:Amlodipine Besilate IP eq. to Amlodipine 5 mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ATORITIC 10MG 10T ALU\/ ALU<\/td>\n | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 10 mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ATORITIC 20MG 10T ALU\/ ALU<\/td>\n | Each film coated tablet contains:Atorvastatin Calcium IP eq. to atorvastatin 20 mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ATORITIC 40MG 10T ALU\/ ALU<\/td>\n | Each film coated tablet contains: Atorvastatin Calcium IP eq. to atorvastatin 40 mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ATORITIC 80 MG<\/td>\n | Each film coated tablet contains: Atorvastatin Calcium IP eq. to atorvastatin 80 mg<\/td>\n <\/tr>\n | ANTI-CHOLINERGIC<\/td>\n | ATROWOK 1ML<\/td>\n | Each 1ml contains: Atropine Sulphate 0.6mg<\/td>\n <\/tr>\n | GENERAL<\/td>\n | BABY GRIPE WATER 150ML (BOX PACK)<\/td>\n | Each 5ml contains: Purified Sarjikakshara 45mg, Sowa tel 0.0009ml, Pudina Tel 0.0002ml, Shatapushpa Tel 0.0007ml<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | CEFPRAZ S 1.50GM (SCH H1)<\/td>\n | Each vial c ontains: Sulbactam Sodium USP eq to Sulbactam 0.5gm, | Cefoperazone Sodium USP eq to Cefoperazone 1gm<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | CEFPRAZ S 1GM (SCH H1)<\/td>\n | Each vial contains: Sulbactam Sodium USP eq to Sulbactam 0.5gm, Cefoperazone Sodium USP eq to Cefoperazone 0.5gm<\/td>\n <\/tr>\n | PROTEIN<\/td>\n | CHOCOMIX PLUS 200GM – CHOCOLATE<\/td>\n | Protein Powder<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | CHYMOWOCK FORTE 20T<\/td>\n | Each enteric coated contains: 100,000 Armour units Enzymatic activity supplied by a purified concentrate which has specific trypsin and Chymotrypsin activity in a ratio of approximately six to one.<\/td>\n <\/tr>\n | ANTIHISTAMIN<\/td>\n | CINWOX 25T<\/td>\n | Each Uncoated tablet contains: Cinnarizine IP 25mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | CIPROSYN IV 100ML<\/td>\n | Each 100ml contains: Ciprofloxacin HCL IP eq to Ciprofloxacin 200 mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | CIPROTAB 500MG 10T<\/td>\n | Each Tablet Contains – Ciprofloxacin HCL IP eq to Ciprofloxacin 500 mg<\/td>\n <\/tr>\n | LAXATIVE <\/td>\n | CRIMAWOK 170ML<\/td>\n | Each 5ml contains: Liquid parafin 3.75ml, Milk of Magnesia 11.25ml<\/td>\n <\/tr>\n | CORTICOSTEROID<\/td>\n | DEFLAWOK 10T<\/td>\n | Each uncoated tablet contains: Deflazacort 6mg<\/td>\n <\/tr>\n | CORTICOSTEROID<\/td>\n | DEFLAWOK SUSP. 30ML<\/td>\n | Each 5ml contains: Deflazacort 6mg<\/td>\n <\/tr>\n | ANTISPASMODIC <\/td>\n | DOTRIWOCK INJ 2 ML<\/td>\n | Each 2ml contains: Dortaverine HCl IP 40mg<\/td>\n <\/tr>\n | ANTIEMETIC<\/td>\n | DOXMINE 10T<\/td>\n | Each enteric coated tablet contains: Doxylamine Succinate USP 10mg, | Pyridoxine Hydrochloride (Vit. B6) IP 10mg<\/td>\n <\/tr>\n REHYDRATION<\/td>\n | ELECTROWOK ORS ORANGE 21 GM<\/td>\n | ORS Each sachet (21.8g) contains: Sodium Chloride IP 2.60g, Potassium Chloride IP 1.50g, Sodium Citrate IP 2.90g, Dextrose Anhydrous IP 13.50g<\/td>\n <\/tr>\n | PPI<\/td>\n | ESOPRAZOLE 20MG 10 TABLET<\/td>\n | Each enteric-coated tablet contains: Esomeprazole Magnesium Trihydrate eq to IP Esomeprazole 20mg<\/td>\n <\/tr>\n | PPI<\/td>\n | ESOPRAZOLE 40MG 10 TABLET<\/td>\n | Each enteric-coated tablet contains: Esomeprazole Magnesium Trihydrate eq to IP Esomeprazole 40mg<\/td>\n <\/tr>\n | PPI<\/td>\n | ESOPRAZOLE DSR 10C<\/td>\n | Each hard gelatine tablet contain: Esomeprazole Magnesium Trihydrate IP 40mg, Domperidone IP 30mg<\/td>\n <\/tr>\n | PPI<\/td>\n | ESOPRAZOLE L 10C<\/td>\n | Each hard gelatin capsules contains: | Esoprazole Magnesium Trihydrate IP eq. to Esoprazole 40mg (a entric coated tablet), Levosulpride 75mg ( as sustained release uncoated tablet)<\/td>\n <\/tr>\n ANTIHEMORRHAGIC<\/td>\n | ETHAWK 250 10T (Disc)<\/td>\n | Each uncoated tablet Contains: Ethamsylate 250mg BP<\/td>\n <\/tr>\n | ANTIHEMORRHAGIC<\/td>\n | ETHAWK 500 10T<\/td>\n | Each uncoated tablet Contains: Ethamsylate 500mg BP<\/td>\n <\/tr>\n | ANTIHEMORRHAGIC<\/td>\n | ETHAWK INJ 2ML<\/td>\n | Each 2ml contains: Ethamsylate 125mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | ETOWOX 120MG ALU-ALU 10T<\/td>\n | Each Film Coated Tablet Contains: Etoricoxib 120mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | ETOWOX 90 MG ALU-ALU 10T<\/td>\n | Each Film Coated Tablet Contains: Etoricoxib IP 90mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | ETOWOX TH4 10T<\/td>\n | Each film coated tablet contains: Etoricoxib IP 60mg, Thoicolchicoside IP 4mg<\/td>\n <\/tr>\n | HEAMATINIC <\/td>\n | FERRIWOK XT 10T (mono)<\/td>\n | Each film coated tablet contain: Ferrous Ascorbate eq to elemental | Iron 100mg, Folic Acid IP 1.5mg<\/td>\n <\/tr>\n MULTIVITAMIN<\/td>\n | FOLIWOCK 30T<\/td>\n | Each uncoated tablet contains: Folic Acid IP 5mg<\/td>\n <\/tr>\n | ANTIFUNGAL<\/td>\n | FUNAZ 150MG 1T<\/td>\n | Each uncoated tablet contains: Fluconazole IP 150mg<\/td>\n <\/tr>\n | ANTIFUNGAL<\/td>\n | FUNAZ 200MG 2T<\/td>\n | Each uncoated tablet contains: Fluconazole IP 200mg<\/td>\n <\/tr>\n | ANTIFUNGAL<\/td>\n | FUNAZ IV 100ml<\/td>\n | Each 100ml contains: Fluconazole USP 200mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | IBUVON 60ML<\/td>\n | Each 5ml contains: Ibuprofen IP 100mg,Paracetamol IP 162.5 mg<\/td>\n <\/tr>\n | NORMAL SALINE<\/td>\n | IV NS 100ML<\/td>\n | Each 100ml contains: Sodium Chloride IP 0.9% gm<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR 250 10 TABLET<\/td>\n | Each film coated tablet contains: Cefuroxime Axetil IP 250mg (eq. To Cefuroxime)<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR 250 4 TABLET<\/td>\n | Each film coated tablet contains: Cefuroxime Axetil IP 250mg (eq. To Cefuroxime)<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR 500 10 TABLET<\/td>\n | Each film coated tablet contains: Cefuroxime Axetil 500mg (eq. To Cefuroxime Anhydrous IP)<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR 500 4 TABLET<\/td>\n | Each film coated tablet contains: Cefuroxime Axetil 500mg (eq. To Cefuroxime Anhydrous IP)<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR CV 10T<\/td>\n | Each flim coated tablet contains: Cefuroxime Axetil IP eq. to cefuroxime 500mg, Potassium Clavulanate 125mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | KEFSTAR DS 125MG (WFI)<\/td>\n | Each 5ml contains: Cefuroxime Axetil 125mg (eq. To Cefuroxime Anhydrous IP)<\/td>\n <\/tr>\n | EYE LUBRICANT<\/td>\n | KLIN EYE 10ml<\/td>\n | Carboxymethylcellulose Sodium IP 0.5%w\/v, Stabilized | OxychloroComplex 0.005%w\/v<\/td>\n <\/tr>\n PROBIOTICS<\/td>\n | LACTOSALT DS 15T<\/td>\n | Each uncoated tablet contains: Lactic Acid Bacillius Viable Spores 120 million<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | LEVOSETRIDE 10T ALU \/ ALU -Rate<\/td>\n | Each film coated tablet contains: Levocetirizine dihydochloride 5mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | LEVOSETRIDE 30ML<\/td>\n | Each 5ml contains: Levocetirizine 2.5mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | LEVOSETRIDE 5MG 10T<\/td>\n | Each film-coated tablet contains: Levocetirizine Hydrochloride IP 5mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | LEVOSETRIDE 60ML SYRUP (CARTON)<\/td>\n | Each 5ml contains: Levocetirizine 2.5mg<\/td>\n <\/tr>\n | COUGH & COLD<\/td>\n | LEVOSETRIDE AM TABS 10’S<\/td>\n | Each film-coated tablet contains: Levocetirizine Hydrochloride IP 5mg, Ambroxol Hydrochloride IP 60mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | LINEZOLID 600MG 10 TAB<\/td>\n | Each film coated tablets: Linezolid Tablets IP 600mg<\/td>\n <\/tr>\n | ANTI-DIARRHEAL<\/td>\n | LOPAMAX 10 T<\/td>\n | Each uncoated tablet contains: Loperamide Hydrochloride IP 2mg<\/td>\n <\/tr>\n | MULTIVITAMIN<\/td>\n | LYCOWOCX-PLUS 200ML<\/td>\n | Each 10ml contains:Lycopene 1000mcg ,Vit. A concentrate (oily form) (As Palmitate) 2500 IU, Vit. E Acetate 10 IU, Ascorbic Acid 50 IU, Selenium (As Sodium Selinate) 35mcg, Zinc (As Zinc Gluconate) 3 mg, Manganese (As Manganese Gluconate) 2mg, Iodine (As Potassium Iodide) 100mcg, Copper (As Cupric Sulphate) 500mcg, Thiamine Hcl | 2mg, Riboflavine 3mg, Pyridoxine Hcl 1.5 mg<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | MAGENTA 30ML INJ. ( PTD )<\/td>\n | Each 2ml contains: Gentamicin Sulphate IP eq to 80mg of Gentamicin<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | MAGENTA INJ. 10ML ( PTD )<\/td>\n | Each 2ml contains: Gentamicin Sulphate IP eq to 80mg of Gentamicin<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | MAGENTA INJ. 20ML ( PTD )<\/td>\n | Each 2ml contains: Gentamicin Sulphate IP eq to 80mg of Gentamicin<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MEFACID FORTE 10T<\/td>\n | Each Tablet contains: Mefanamic Acid 500mg + Paracetamol 325mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MEFACID FORTE SUSP<\/td>\n | Each 5ml contains: Mefenamic Acid 100mg, Paracetamol 250mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MEFACID PLUS SUSP<\/td>\n | Each 5ml contains: Mefenamic Acid 50mg, Paracetamol 125mg<\/td>\n <\/tr>\n | ANTISPASMODIC <\/td>\n | MEFACID SPAS 10T<\/td>\n | Each uncoated tablet contains: Mefenamic Acid IP 250mg, | Dicyclomine HCl IP 10mg<\/td>\n <\/tr>\n CORTICOSTEROID<\/td>\n | MERIDECA 30ML INJ. ( PTD )<\/td>\n | Each ml contains: Dexamethasone Sodium Phosphate IP eq to | Dexamethasone Phosphate 4mg<\/td>\n <\/tr>\n CORTICOSTEROID<\/td>\n | MERIDECA INJ. 10ML ( PTD )<\/td>\n | Each ml contains: Dexamethasone Sodium Phosphate IP eq to | Dexamethasone Phosphate 4mg<\/td>\n <\/tr>\n CORTICOSTEROID<\/td>\n | MERIDECA INJ. 20ML ( PTD )<\/td>\n | Each ml contains: Dexamethasone Sodium Phosphate IP eq to | Dexamethasone Phosphate 4mg<\/td>\n <\/tr>\n COUGH & COLD<\/td>\n | MERIDRYL 100ML<\/td>\n | Each 5 ml contains: Diphenhydramine Hydrochloride IP 14.08mg, | Ammonium Chloride IP 138 mg, Sodium Citrate 57.03mg, Mentholated Syrupy Base<\/td>\n <\/tr>\n ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL 250MG SUSP 60ML<\/td>\n | Each 5ml contains: Paracetamol IP 250mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL 125MG SUSP 60ML<\/td>\n | Each 5ml contains: Paracetamol IP 125mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL 500 10 TABLET<\/td>\n | Each uncoated tablet contains: Paracetamol IP 500mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL 650 10 TABLET<\/td>\n | Each tablet contains: Paracetamol IP 650mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL DROPS 15ML<\/td>\n | Each 1ml contain: Pracetamol IP 100mg<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | MERIMOL IV 100ML<\/td>\n | Each 100ml contain: Pracetamol 1000mg<\/td>\n <\/tr>\n | BRONCHODILATOR <\/td>\n | MERIPHYLLIN 2ML<\/td>\n | Each ml contains: Etolyline IP Theophyline IP Anhydrous 84.7mg Eq to | TheophylineIP hydrate 25.3mg<\/td>\n <\/tr>\n ANALGESICS\/ANTIPYRETICS<\/td>\n | MERISULIDE PLUS 10T ( 325 ) BLISTER<\/td>\n | Each uncoated tablet contains: Nimesulide BP 100mg, Paracetamol | 325mg<\/td>\n <\/tr>\n ANALGESICS\/ANTIPYRETICS<\/td>\n | MERISULIDE PLUS 10T ( 325 ) BLISTER (Bi- | Layer)<\/td>\n Each uncoated tablet contains: Nimesulide BP 100mg, Paracetamol | 325mg<\/td>\n <\/tr>\n ANALGESICS\/ANTIPYRETICS<\/td>\n | MERISULIDE PLUS 10T ( GOLDEN PVC ) – | 325<\/td>\n Each uncoated tablet contains: Nimesulide BP 100mg | Paracetamol 325mg<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | MONTEWOK – BL TABLETS<\/td>\n | Each film coated tablet contains: Montelukast Sodium IP eq to | Montelukast 10mg, Belastine 20mg IP<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | MONTEWOK – LC SYRUP 30ML<\/td>\n | Each 5ml contain Montelukast Sodium 4mg, Levocetirizine Dihydrochloride | 2.5mg<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | MONTEWOK – LC SYRUP 60ML<\/td>\n | Each 5ml contain Montelukast Sodium 4mg, Levocetirizine Dihydrochloride | 2.5mg<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | MONTEWOK – LC TABLETS 10’S<\/td>\n | Each film coated tablet contains: Montelukast Sodium IP eq to | Montelukast 10mg, Levocetirizine Dihydrochloride IP 5mg<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | MONTEWOK LC KID 10T<\/td>\n | Each film coated tablet contains: Montelukast Sodium IP eq to | Montelukast 5mg, Levocetirizine Dihydrochloride IP 2.5mg<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | MUPIWOK 5 GM<\/td>\n | Composition: Mupirocin IP 2.0% w\/w<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | NOSOPENEM 1GM (SCH H1)<\/td>\n | Each vial contains: Meropenem Trihydrate IP eq to Anhydrous Meropenem 1000mg Sodium Carbonate IP. eq to Sodium 90.2mg | (Added as buffer)<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | NOSOPENEM 500MG INJ (SCH H1)<\/td>\n | Each Vial Contains: Meropenam Trihydrate eq. to Anhydrous Meropenam 500mg, Sodium Carbonate IP eq. to Sodium 45.1mg | (Added as a buffer)<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | OFLOWOCK 10 TABLET<\/td>\n | Each film coated tablet contains: Ofloxacin IP 200mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | OFLOWOCK 200 10T ALU ALU<\/td>\n | Each film coated tablet contains: Ofloxacin IP 200mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | OFLOWOCK-OZ TABLETS 10’S<\/td>\n | Each film coated tablet contains: Ofloxacin IP 200mg, Ornidazole IP | 500mg<\/td>\n <\/tr>\n PPI<\/td>\n | OMALCER 15 CAPS ( SIZE 3 )<\/td>\n | Each hard gelatin capsules contains: Omeprazole IP 20mg (As enteric | coated pellets)<\/td>\n <\/tr>\n PPI<\/td>\n | OMALCER D 15 CAPSULES<\/td>\n | Each hard gelatin capsules contains: | Omeprazole IP 20mg, Domeperidone BP 10mg<\/td>\n <\/tr>\n PPI<\/td>\n | Omiwok 20C<\/td>\n | Each hard gelatin capsules contains: Omeprazole IP 20mg (As enteric | coated pellets)<\/td>\n <\/tr>\n ANTIEMETIC<\/td>\n | ONDITRON SUSP. 30ML<\/td>\n | Each 5ml contains: Ondansetron Hydrochloride IP eq. to Ondansetron | 2 mg<\/td>\n <\/tr>\n ANTIEMETIC<\/td>\n | ONDITRON 2MG 2ML<\/td>\n | Each ml contains: Ondansetron Hydrochloride IP eq. to Ondansetron | 2mg<\/td>\n <\/tr>\n ANTIEMETIC<\/td>\n | ONDITRON 4MG 10T<\/td>\n | Each film coated tablet contains: Ondansetron Hydrochloride IP eq to | Ondansetron 4mg<\/td>\n <\/tr>\n ANTIEMETIC<\/td>\n | ONDITRON MD TAB 10T<\/td>\n | Each uncoated mouth dissolving tablet contains: Ondasetron IP 4mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | OXYTETRA INJECTION 30ML<\/td>\n | Each ml contains: Oxytetracycline IP Eq. To anhydrous Oxytetracycline | 50mg, Lidocaine USP 2% w\/v<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK – D 10T<\/td>\n | Each enteric-coated tablet contains:Pantoprazole Sodium eq. To | Pantoprazole 40mg, Domperidone B.P.10mg<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK INJ 10ML (W\/T)<\/td>\n | Each Vial contains: Pantoprazole Sodium Eq. To Pantoprazole 40mg<\/td>\n <\/tr>\n | PPI<\/td>\n | PENTOWOK 10T<\/td>\n | Each enteric-coated tablet contains: Pantoprazole Sodium | Sesquihydrate eq. To Pantoprazole 40mg<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK 40 MG 15T<\/td>\n | Each enteric-coated tablet contains: Pantoprazole Sodium | Sesquihydrate eq. To Pantoprazole 40mg<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK DSR 10 CAP<\/td>\n | Each hard gelatin capsule contains: Pantoprazole Sodium IP (as sesquihydrate) Eq. to Pantoprazole 40mg (as enteric coated pellets), | Domperidone IP 30mg (as sustained release pellets)<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK DSR 20 CAP<\/td>\n | Each hard gelatin capsule contains: Pantoprazole Sodium IP (as sesquihydrate) Eq. to Pantoprazole 40mg (as enteric coated pellets), | Domperidone IP 30mg (as sustained release pellets)<\/td>\n <\/tr>\n PPI<\/td>\n | PENTOWOK L 10C (MONO CARTON)<\/td>\n | Each Hard Gelatin capsule contains: Pantoprazole sodium IP equivalent to Pantoprazole \u2026\u2026 40mg (As enteric coated pellets) Levosulpiride …… 75 mg (as Sustained relese Tablets | \u2026 q.s. Excipients q.s. Approved Colour used in empty capsule shells<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | PIPWOX – T INJ. 4.5G ( W\/O TRAY ) -rate<\/td>\n | Each Vial Contains: Sterile Piperacilin Sodium 4gm,Tazobactam | Sodium 0.5gm<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | PIPWOX – T INJ. 4.5G ( WFI )<\/td>\n | Each Vial Contains: Sterile Piperacilin Sodium 4gm,Tazobactam | Sodium 0.5gm<\/td>\n <\/tr>\n CORTICOSTEROID<\/td>\n | PREDNIWOCK 4MG 10T<\/td>\n | Each Tablet contains: Methylprednisolone 4mg<\/td>\n <\/tr>\n | CORTICOSTEROID<\/td>\n | PREDNIWOCK 8MG<\/td>\n | Each Tablet contains: Methylprednisolone 8mg<\/td>\n <\/tr>\n | GENERAL<\/td>\n | PREGNIWOK CARD ( NEW )<\/td>\n | HCG Pregnancy kit<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ROZUWOK 10MG 10T<\/td>\n | Each Uncoated Tablet Contains : Rosuvastatin Calcuim IP eq. to Rosuvastation 10 mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | ROZUWOK 20MG 10T<\/td>\n | Each uncoated Tablet contains: Rousvastatin calcium IP eq. to | Rosuvastatin 20mg<\/td>\n <\/tr>\n CARDIAC<\/td>\n | ROZUWOK 5MG 10T<\/td>\n | Each Uncoated Tablet Contains : Rosuvastatin Calcuim IP eq. to | Rosuvastation 5 mg<\/td>\n <\/tr>\n CARDIAC<\/td>\n | ROZUWOK-F 10 TAB<\/td>\n | Each Uncoated Tablet Contains : Rosuvastatin Calcuim IP eq. to | Rosuvastation 10 mg , Fenofibrate 160mg<\/td>\n <\/tr>\n ANALGESICS\/ANTIPYRETICS<\/td>\n | SERIWOK 10MG 10T<\/td>\n | Each enteric coated tablet contains: Serratiopeptidase 10mg (20,000 Serratiopeptidase units)<\/td>\n <\/tr>\n | ANALGESICS\/ANTIPYRETICS<\/td>\n | SERIWOK-D 10T<\/td>\n | Each film coated tablet contains: Serratiopeptidase IP 10mg (20,000 Serratiopeptidase units), Diclofenac Potassium IP 50mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | SETRIDE 10T<\/td>\n | Each film coated tablet contains : Cetrizine Dihydrochloride IP 10mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | SETRIDE SOFTGEL 10C<\/td>\n | Each 5ml Contains: Cetrizine Hydrochloride IP 10mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | SETRIDE SYRUP 30ML<\/td>\n | Each 5ml Contains: Cetrizine Hydrochloride IP 5mg<\/td>\n <\/tr>\n | ANTISPASMODIC <\/td>\n | SPASIDEX 10 TAB ( 325 )<\/td>\n | Each uncoated tablet contains: Dicyclomine HCl IP 20mg, Paracetamol IP 325mg<\/td>\n <\/tr>\n | ANTISPASMODIC <\/td>\n | SPASIDEX DROPS 10ML<\/td>\n | Each ml contains: DICYCLOMINE-10MG + SIMETHICONE-40MG<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | TELMIWOCK 20 10T<\/td>\n | Each film coated tablet contains: Telmisartan IP 20 MG<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | TELMIWOCK 40MG 10T<\/td>\n | Each film coated tablet contains: Telmisartan IP 40 MG<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | TELMIWOCK 80MG 10T<\/td>\n | Each film coated tablet contains: Telmisartan IP 80 MG<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | TELMIWOCK AM 10T<\/td>\n | Each uncoated tablet contains:Telmisartan IP 40mg, Amlodipine Besilate IP eq. to Amlodipine 5mg<\/td>\n <\/tr>\n | CARDIAC<\/td>\n | TELMIWOCK CH 10T<\/td>\n | Each uncoated tablet contains:Telmisartan IP 40mg, Chlorthalidone | 12.5 MG<\/td>\n <\/tr>\n CARDIAC<\/td>\n | TELMIWOCK H 10T<\/td>\n | Each uncoated bilayered tablet contains:Telmisartan IP 40 mg, | Hydrochlorothiazide IP 12.5mg<\/td>\n <\/tr>\n CARDIAC<\/td>\n | TELMIWOCK H 80MG 10T<\/td>\n | Each uncoated tablet contains: Telmisartan IP 80mg | Hydrochlorothiazide IP 12.5 mg<\/td>\n <\/tr>\n CARDIAC<\/td>\n | TELMIWOCK-AMH 10T<\/td>\n | Each uncoated tablet contains: Telmisartan IP 40mg, Amlodipine | Besilate IP eq. to Amlodipine 5mg, Hydrochlorothiazide IP 12.5mg<\/td>\n <\/tr>\n ANTIFUNGAL<\/td>\n | TERBIWOK 250MG 7T<\/td>\n | Each uncoated tablet contain Terbinafine HCl USP eq to Terbinafine | 250 mg<\/td>\n <\/tr>\n ANTIHEMORRHAGIC<\/td>\n | TEXAWOCK – MF 10T<\/td>\n | Tranexamic Acid 500mg + Mefenamic 250mg<\/td>\n <\/tr>\n | ANTIHEMORRHAGIC<\/td>\n | TEXAWOCK 5ML INJ<\/td>\n | Each 5ml contains: Tranexamic acid IP 500mg<\/td>\n <\/tr>\n | GENERAL<\/td>\n | THERMOMETER<\/td>\n | Digitial Thermometer<\/td>\n <\/tr>\n | CORTICOSTEROID<\/td>\n | TIPICORT 1ML<\/td>\n | Each vial contains: Triamcinolone Acetonide IP 40mg<\/td>\n <\/tr>\n | MOUTH ULCER<\/td>\n | ULCIWOK 10GM<\/td>\n | Choline Salicylate 8.7% w\/v, Lignocaine HCl 2.0% w\/w, | Benzalkonium chloride solution IP 0.01% w\/w<\/td>\n <\/tr>\n MOUTH ULCER<\/td>\n | ULCIWOK 10GM (PAN FLAVOUR)<\/td>\n | Choline Salicylate 8.7% w\/v, Lignocaine HCl 2.0% w\/w, | Benzalkonium chloride solution IP 0.01% w\/w<\/td>\n <\/tr>\n DIGESTIVE <\/td>\n | ULTRAZYME PLUS 200ML (AYURVEDIC)<\/td>\n | Each 5 ml Contains: Pippli (Piper longam) 7.5mg, Kalimirch (Piper nigrum) 6mg, Amla (Emblica officinalis) 33.3mg, Harad (Terminalia chebula) 33.3mg, Adrak (Zingiber officinale) 12.5mg, Ajwain (Ptychotis ajowan) 16.67mg, Jeera (Cuminum cyminum) 16.67mg, Anardana (Punica granatum) 6mg, Saunf (Foeniculum vulgare) 14.29 mg, Senna (Cassia angustifolia) 5mg, Kalanamak (Unaqua Sodium | Chloride) 30 mg<\/td>\n <\/tr>\n ERECTILE DYSFUNCTION<\/td>\n | VIGO FORCE 1X4T<\/td>\n | Each film coated tablet contains: Sildenafil Citrate IP 50mg, | Dapoxetine Hcl IP 30mg<\/td>\n <\/tr>\n ERECTILE DYSFUNCTION<\/td>\n | VIGOXXX 100 4T<\/td>\n | Each uncoated tablet contain: Sildenafil Tablet 100mg<\/td>\n <\/tr>\n | ANTI-DIABETICS<\/td>\n | VOGLIWOK 0.2MG 10T<\/td>\n | Each uncoated tablet contains: Voglibose IP 0.2 mg<\/td>\n <\/tr>\n | ANTI-DIABETICS<\/td>\n | VOGLIWOK 0.3MG 10T<\/td>\n | Each uncoated tablet contains: Voglibose IP 0.3 mg<\/td>\n <\/tr>\n | ANTACID<\/td>\n | WOCAIN A GEL 200ML (MINT)<\/td>\n | Each 5 ml (one teaspoonful) contains: | Oxetacaine B.P. 10mg Aluminium Hydroxide 0.291gm (Added as Dried Aluminium Hydroxide Gel I.P. 380mg) Magnesium Hydroxide I.P. 98mg (added as Magnesium Hydrooxide paste)<\/td>\n <\/tr>\n ANAESTHETICS<\/td>\n | WOCAINE GEL 30G<\/td>\n | Lidocaine Hydrochloride IP Equivalent to anhydrous Lidocaine Hydrochloride.. 2.0% w\/v Methyl paraben IP | 0.061% w\/v Propyl paraben IP 0.027% w\/v Water soluble jelly base in Purified water IP q.s. ( Lignocaine )<\/td>\n <\/tr>\n HEAMATINIC <\/td>\n | WOFER S INJ 5ML<\/td>\n | Each ml contains: Ferric Hydroxide in complex with Sucrose equivalent | to elemental Iron 20mg<\/td>\n <\/tr>\n ANTIBIOTICS<\/td>\n | WOFLOX 200 10T<\/td>\n | Each film coated tablet contains: Ofloxacin IP 200mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | WOFLOX IV 100ML<\/td>\n | Each 100ml contains: Ofloxacin IP 200mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | WOFLOX-OZ 10T rate<\/td>\n | Each film coated tablet contains: Ofloxacin IP 200mg, Ornidazole IP | 500mg<\/td>\n <\/tr>\n HEAMATINIC <\/td>\n | WOFOL Z 15C<\/td>\n | Each hard Gelatin Capsule Contains: | Elemental iron in the form of Carbonyl iron 50mg, Folic acid 0. 5mg, Zinc sulphate monohydrate USP 61.8mg eq. to 22.5mg of elemental zinc<\/td>\n <\/tr>\n ANTACID<\/td>\n | WOGENE 170ML + MPS (MINT)<\/td>\n | Each 10ml contains: Activated dimethicone IP (Polydimethylsiloxane)- 50mg, Dried Aluminium Hydroxide Gel Ip 250mg (Added as Aluminium Hydroxide Paste) Magnesium Hydroxide IP 250mg (Added as Magnesium Hydroxide Paste) Sorbitol base q.s.<\/td>\n <\/tr>\n | ANTACID<\/td>\n | WOGENE 170ML MPS (MINT)<\/td>\n | Each 5ml contains: Activated dimethicone IP (Polydimethylsiloxane;- 25mg, Dried Aluminium Hydroxide Gel Ip 200mg (Added as Aluminium Hydroxide Paste) Magnesium Hydroxide IP 200mg (Added as Magnesium Hydroxide Paste) Sorbitol base q.s.<\/td>\n <\/tr>\n | DISINFECTANT<\/td>\n | WOLON 1000ML<\/td>\n | Chlorhexidine Gluconate Solution IP 0.3% v\/v, Cetrimide IP 0.6% w\/v<\/td>\n <\/tr>\n | DISINFECTANT<\/td>\n | WOLON 100ML<\/td>\n | Chlorhexidine Gluconate Solution IP 0.3% v\/v, Cetrimide IP 0.6% w\/v<\/td>\n <\/tr>\n | REHYDRATION<\/td>\n | WOLYTE-EL 21.8G<\/td>\n | Each sachet (21.8g) contains: Sodium Chloride IP 2.60g, Potassium Chloride IP 1.50g, Sodium Citrate IP 2.90g, Dextrose | Anhydrous IP 13.50g<\/td>\n <\/tr>\n REHYDRATION<\/td>\n | Wolyte-EL ORS 200ml (Tetra Pack)<\/td>\n | Each pack of 200ml contains: Sodium Chloride IP 0.52g, Potassium Chloride IP 0.30g, Sodium Citrate IP 0.58g, Dextrose | Anhydrous IP 2.70g<\/td>\n <\/tr>\n CORTICOSTEROID<\/td>\n | WOSONE 5ML req rate<\/td>\n | Each vial contains: Hydrocortisone Sodium Succinate USP | eq. to Hydrocortisone 100mg<\/td>\n <\/tr>\n ANTISEPTICS<\/td>\n | WO-SPIRIT SOLUTION 100ML -rate<\/td>\n | Isopropyl Alcohol IP 68% to 72% v\/v, Purified Water IP Q.S. | Antiseptic Surgical Solution<\/td>\n <\/tr>\n ANTISEPTICS<\/td>\n | WO-SPIRIT SOLUTION 400ML -rate<\/td>\n | Isopropyl Alcohol IP 68% to 72% v\/v, Purified Water IP Q.S. | Antiseptic Surgical Solution<\/td>\n <\/tr>\n ANTI-ALLERGICS<\/td>\n | WOTRIZINE H10 MG TAB<\/td>\n | Each Film coated tablet contains: Hydroxyzine HCl IP 10mg<\/td>\n <\/tr>\n | ANTI-ALLERGICS<\/td>\n | WOTRIZINE H25 MG TAB<\/td>\n | Each Film coated tablet contains: Hydroxyzine HCl IP 25mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | ZEKACIN 100MG 2ML INJ.<\/td>\n | Each 2ml contains: Amikacin Sulphate IP eq to Amikacin 100mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | ZEKACIN 250MG 2ML INJ.<\/td>\n | Each 2ml contains: Amikacin Sulphate IP eq to Amikacin 250mg<\/td>\n <\/tr>\n | ANTIBIOTICS<\/td>\n | ZEKACIN 500MG 2ML INJ.<\/td>\n | Each 2ml contains: Amikacin Sulphate IP eq to Amikacin 500mg<\/td>\n <\/tr>\n \n<\/tbody><\/table>\n<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":" | Quality Generics Therapeutic Use Brand Name Composition URINE ALKALIZER ALKAWOCK 100ML Each 5ml contains: Disodium Hydrogen Citrate BP 1.25g ANTI-HELMENTICS ALZAD 1T Each uncoated chewable tablet contains: Albendazole IP 400mg ANTI-HELMENTICS ALZAD SUSP 10ML Each 5ml contains: Albendazole IP 200mg CARDIAC AMLOWOCK- 5 Each uncoated Tablet Contains:Amlodipine Besilate IP eq. to Amlodipine 5 mg CARDIAC … <\/p>\n |